Cancer Clinical Trials

Breast

  • Alliance A011202 - A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

  • Alliance A011401 - Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

  • Alliance A011502 - A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Digestive/Gastrointenstinal

  • Clinical Genomics CG001 - Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed with Colorectal Cancer

Genetics

  • ECOG-ACRIN EAY-131 - A Trial That Aims to Establish Whether Patients With Tumor Mutations, Amplifications Or Translocations in One of the Genetic Pathways of Interest Are Likely to Derive Clinical Benefit If Treated With Agents Targeting That Specific Pathway In A Single-Arm Design

Genitourinary

  • Alliance A031501 - Phase III Randomized Adjuvant Study of MK-3475(Pembrolizumab) In Muscle Invasive And Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation

Head and Neck

  • Galera GTI-4419-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer

Hematologic/Blood

  • Pharmacyclics PCYC-1134M-CA - informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

Respiratory/Thoracic

  • Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

  • Alliance A211401 - Reducing Surgical Complications In Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes

Skin

  • ECOG-ACRIN EA6134 - A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab At Progression vs. Ipilimumab + Nivolumab Followed By Dabrafenib + Trametinib At Progression in Patients With Advanced BRAFV600 Mutant Melanoma